The DOI matches its Crossref record; 15 of the 23 references it cites were found in a registry or an index, and 8 are not checked yet.
Gene Expression Alterations in Prostate Cancer Predicting Tumor Aggression and Preceding Development of Malignancy
Abstract
Purpose: The incidence of prostate cancer is frequent, occurring in almost one-third of men older than 45 years. Only a fraction of the cases reach the stages displaying clinical significance. Despite the advances in our understanding of prostate carcinogenesis and disease progression, our knowledge of this disease is still fragmented. Identification of the genes and patterns of gene expression will provide a more cohesive picture of prostate cancer biology. Patients and Methods: In this study, we performed a comprehensive gene expression analysis on 152 human samples including prostate cancer tissues, prostate tissues adjacent to tumor, and organ donor prostate tissues, obtained from men of various ages, using the Affymetrix (Santa Clara, CA) U95a, U95b, and U95c chip sets (37,777 genes and expression sequence tags). Results: Our results confirm an alteration of gene expression in prostate cancer when comparing with nontumor adjacent prostate tissues. However, our study also indicates that the gene expression pattern in tissues adjacent to cancer is so substantially altered that it resembles a cancer field effect. Conclusion: We also found that gene expression patterns can be used to predict the aggressiveness of prostate cancer using a novel model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Classical and Modern Regression With Applications.
Steinhorst, R. K., & Myers, R. H. (1988) · Journal of the American Statistical Association · doi:10.2307/2288958 · Cited by 3,690
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang‐Rodriguez, J., Moskaluk, C. A., Frierson, H. F., & Hampton, G. M. (2001) · PubMed · Cited by 856
Latulippe, É., Satagopan, J. M., Smith, A., Scher, H. I., Scardino, P. T., Reuter, V. E., & Gerald, W. L. (2002) · PubMed · Cited by 518
Cited by
Items 301–400 of 761
Novel, Potent Anti-Androgens of Therapeutic Potential: Recent Advances and Promising Developments
Vasaitis, T. S., & Njar, V. C. O. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.14 · Cited by 41
PDLIM4, An Actin Binding Protein, Suppresses Prostate Cancer Cell Growth
Vanaja, D. K., Grossmann, M. E., Cheville, J. C., Gazi, M. H., Gong, A., Zhang, J. S., Ajtai, K., Burghardt, T. P., & Young, C. Y. F. (2009) · Cancer Investigation · doi:10.1080/07357900802406319 · Cited by 40
Significance of TRIM29 and β-catenin expression in non-small-cell lung cancer
Zhou, Z., Yang, G.-Y., Zhou, J., & Yu, M. (2012) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2012.04.015 · Cited by 40
Bisoffi (2009) · International Journal of Oncology · doi:10.3892/ijo_00000365 · Cited by 40
The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis
Koziol, J. A., Feng, A. C., Jia, Z., Wang, Y., Goodison, S., McClelland, M., & Mercola, D. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn354 · Cited by 39
Zhu, J., Cui, L., Xu, A., Yin, X., Li, F., & Gao, J. (2017) · BMC Cancer · doi:10.1186/s12885-017-3155-2 · Cited by 41
Prostate Cancer as a Model System for Genetic Diversity in Tumors
Squire, J. A., Park, P. C., Yoshimoto, M., Alami, J., Williams, J. L., Evans, A. J., & Joshua, A. M. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-387688-1.00007-7 · Cited by 40
Kim, S.-H., Lee, S., Piccolo, S., Allen‐Brady, K., Park, E., Chun, J. N., Kim, T., Cho, N., Kim, I. G., So, I., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.010 · Cited by 38
Zheng, Y., Asara, J. M., & Tyner, A. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.298117 · Cited by 38
Worst, T. S., Meyer, Y., Gottschalt, M., Weis, C., von Hardenberg, J., Frank, C., Steidler, A., Michel, M. S., & Erben, P. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3872 · Cited by 42
Targeting Lyn regulates Snail family shuttling and inhibits metastasis
Thaper, D., Vahid, S., Nip, K. M., Moskalev, I., Shan, X., Frees, S., Roberts, M. E., Ketola, K., Harder, K. W., Gregory, C. Y., et al. (2017) · Oncogene · doi:10.1038/onc.2017.5 · Cited by 39
Sarwar, M., Sandberg, S., Abrahamsson, P., & Persson, J. L. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.08.019 · Cited by 45
Luce, L. N., Abbate, M., Cotignola, J., & Giliberto, F. (2016) · Oncotarget · doi:10.18632/oncotarget.10426 · Cited by 41
Xia, J., Wang, F., Wang, L., & Fan, Q. (2012) · Tumor Biology · doi:10.1007/s13277-012-0553-6 · Cited by 39
Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer
Myers, J. S., von Lersner, A. K., Robbins, C. T., & Sang, Q. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145322 · Cited by 52
SOX4 is activated by C-MYC in prostate cancer
Dong, H., Hu, J., Wang, L., Qi, M., Lü, N., Tan, X., Yang, M., Bai, X., Zhan, X., & Han, B. (2019) · Medical Oncology · doi:10.1007/s12032-019-1317-6 · Cited by 37
Hsieh, A. C., Small, E. J., & Ryan, C. J. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70316-9 · Cited by 38
Yang, C., Melhuish, T. A., Spencer, A., Li, N., Hao, Y., Jividen, K., Harris, T. E., Snow, C. J., Frierson, H. F., Wotton, D., et al. (2017) · The Prostate · doi:10.1002/pros.23400 · Cited by 37
Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies
He, D.-M., Ren, B.-G., Liu, S., Tan, L.-Z., Cieply, K. M., Tseng, G. C., Yu, Y., & Luo, J.-H. (2017) · Oncogene · doi:10.1038/onc.2017.123 · Cited by 36
Self-citationInsulin Enhances Migration and Invasion in Prostate Cancer Cells by Up-Regulation of FOXC2
Sarkar, P. L., Lee, W., Williams, E. D., Lubik, A. A., Stylianou, N., Shokoohmand, A., Lehman, M., Hollier, B. G., Gunter, J. H., & Nelson, C. C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00481 · Cited by 36
The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression
Lucas, N., & Day, M. L. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22087 · Cited by 36
Kashyap, V., & Bonavida, B. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.12 · Cited by 36
Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells
Recouvreux, M. V., Wu, B. J., Gao, A. C., Zonis, S., Chesnokova, V., Bhowmick, N. A., Chung, L. W. K., & Melmed, S. K. (2017) · Endocrinology · doi:10.1210/en.2016-1939 · Cited by 36
C/EBPα redirects androgen receptor signaling through a unique bimodal interaction
Zhang, J., Gonit, M., Salazar, M. D., Shatnawi, A. A., Shemshedini, L., Trumbly, R. J., & Ratnam, M. (2009) · Oncogene · doi:10.1038/onc.2009.373 · Cited by 38
Using the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy Negative Patients
Truong, M., Yang, B., Livermore, A. T., Wagner, J. L., Weeratunga, P., Huang, W., Dhir, R., Nelson, J. B., Lin, D. W., & Jarrard, D. F. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.074 · Cited by 35
Self-citationHOXC6 promotes cervical cancer progression via regulation of Bcl‐2
Wang, Y., Wang, C., Liu, N., Hou, J., Xiao, W., & Wang, H. (2018) · The FASEB Journal · doi:10.1096/fj.201801099rr · Cited by 35
Kumano, Y., Hasegawa, Y., Kawahara, T., Yasui, M., Miyoshi, Y., Matsubara, N., & Uemura, H. (2019) · BioMed Research International · doi:10.1155/2019/9450838 · Cited by 38
Kawahara, R., Recuero, S. D. C., Nogueira, F. C. S., Domont, G. B., Leite, K. R. M., Srougi, M., Thaysen‐Andersen, M., & Palmisano, G. (2019) · PROTEOMICS · doi:10.1002/pmic.201900174 · Cited by 35
BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells
Peña‐Hernández, R., Aprigliano, R., Frommel, S. C., Pietrzak, K., Steiger, S., Roganowicz, M., Lerra, L., Bizzarro, J., & Santoro, R. (2021) · EMBO Reports · doi:10.15252/embr.202153014 · Cited by 37
Gene Expression Profiles in Cancers and Their Therapeutic Implications
Creighton, C. J. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000638 · Cited by 37
Gelman, I. H. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8264 · Cited by 37
Integrative Network Biology: Graph Prototyping for Co-Expression Cancer Networks
Kugler, K., Mueller, L. A. J., Graber, A., & Dehmer, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022843 · Cited by 35
Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer
Fujimura, T., Takahashi, S., Urano, T., Kumagai, J., Murata, T., Takayama, K., Ogushi, T., Horie-Inoue, K., Ouchi, Y., Kitamura, T., et al. (2009) · Urology · doi:10.1016/j.urology.2009.02.033 · Cited by 34
PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
Miller, K. A., Degan, S. E., Wang, Y., Cohen, J., Ku, S., Goodrich, D. W., & Gelman, I. H. (2023) · Oncogene · doi:10.1038/s41388-023-02875-4 · Cited by 34
Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer
Xu, S., Adisetiyo, H., Tamura, S., Grande, F., Garofalo, A., Roy‐Burman, P., & Neamati, N. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.228 · Cited by 34
Tang, Z., Cui, Q., Dong, Q., Xu, K., & Wang, E. (2013) · Tumor Biology · doi:10.1007/s13277-013-0843-7 · Cited by 36
Hic-5 influences genomic and non-genomic actions of the androgen receptor in prostate myofibroblasts
Leach, D. A., Need, E. F., Trotta, A. P., Grubisha, M. J., DeFranco, D. B., & Buchanan, G. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.004 · Cited by 34
On reliable discovery of molecular signatures
Nilsson, R., Björkegren, J., & Tegner, J. N. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-38 · Cited by 35
Zoni, E., Minoli, M., Bovet, C., Wehrhan, A., Piscuoglio, S., Ng, C. K. Y., Gray, P. C., Spahn, M., Thalmann, G. N., & Julio, M. K. (2019) · BMC Cancer · doi:10.1186/s12885-019-6418-2 · Cited by 34
Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in human prostate cancer
Xie, M., Xie, R., Xie, S., Wu, Y., Wang, W., Li, X., Xu, Y., Liu, B., Zhou, Y., Wang, T., et al. (2020) · Cell Biology International · doi:10.1002/cbin.11418 · Cited by 38
Varışlı, L. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0524 · Cited by 34
Stokes, T. H., Moffitt, A. B., Phan, J. H., & Wang, M. D. (2007) · Annals of Biomedical Engineering · doi:10.1007/s10439-007-9313-y · Cited by 34
Jones, A. C., Antillon, K. S., Jenkins, S. M., Janos, S. N., Overton, H. N., Shoshan, D. S., Fischer, E. G., Trujillo, K. A., & Bisoffi, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119314 · Cited by 34
The awakening of an advanced malignant cancer: An insult to the mitochondrial genome
Cook, C. C., & Higuchi, M. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.08.017 · Cited by 34
Chen, Y., Blackwell, T. W., Chen, J., Gao, J., Lee, A. W., & States, D. J. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030063 · Cited by 34
The pathogenesis of prostate cancer: from molecular to metabolic alterations
Benedettini, E., Nguyen, P., & Loda, M. F. (2008) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2008.03.001 · Cited by 34
DNA Methylation and Field Cancerization
Ramachandran, K. J., & Singal, R. (2012) · Epigenomics · doi:10.2217/epi.12.12 · Cited by 34
Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer Cells
Zhang, W., Yi, B., Wang, C., Chen, D., Bae, S., Wei, S., Guo, R., Lu, C., Nguyen, L. L. H., Yang, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1927 · Cited by 33
Dai, L., Song, Z., Wei, D., Zhang, J., Liang, J., Wang, B.-B., Ma, W.-T., Li, L., Dang, Y.-L., Zhao, L., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01729-3 · Cited by 33
Discovery and Classification of Fusion Transcripts in Prostate Cancer and Normal Prostate Tissue
Luo, J., Liu, S., Zuo, Z., Chen, R., Tseng, G. C., & Yu, Y. P. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.03.008 · Cited by 33
Self-citationTan, L., Song, Y., Nelson, J. B., Yu, Y. P., & Luo, J. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.010 · Cited by 33
Self-citationNuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer
Wang, Z., Wu, D., Ng, C., Teoh, J. Y., Yu, S., Wang, Y., & Chan, F. L. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0280 · Cited by 36
CUL4B/miR‐33b/C‐MYC axis promotes prostate cancer progression
Zhao, M., Qi, M., Li, X., Hu, J., Zhang, J., Jiao, M., Bai, X., Peng, X., & Han, B. (2019) · The Prostate · doi:10.1002/pros.23754 · Cited by 32
Peng, S., Du, T., Wu, W., Chen, X., Lai, Y., Zhu, D., Wang, Q., Ma, X., Lin, C., Li, Z., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.05.021 · Cited by 32
Lin, C., Jan, Y., Kuo, L., Wang, B., Huo, C., Jiang, S. S., Chen, S., Kuo, Y., Chang, C., & Chuu, C. (2018) · Cancer Science · doi:10.1111/cas.13776 · Cited by 32
Nuclear iASPP may facilitate prostate cancer progression
Morris, E. V., Cerundolo, L., Lu, M. M., Verrill, C. L., Fritzsche, F., White, M. J., Thalmann, G. N., ten Donkelaar, C. S., Ratnayaka, I., Salter, V., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.442 · Cited by 32
Lewis, E. M., Wilkinson, A. S., Jackson, J. S., Mehra, R., Varambally, S., Chinnaiyan, A. M., & Wilkinson, J. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407650 · Cited by 32
Jia, P., Liu, Y., & Zhao, Z. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-s3-s13 · Cited by 32
EXO1/P53/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression
Wang, Z., Chao, Z., Wang, Q., Zou, F., Song, T., Xu, L., Ning, J., & Fan, C. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04822-z · Cited by 31
Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer
Lefort, K., Ostano, P., Grand, M. M., Calpini, V., Scatolini, M., Farsetti, A., Dotto, G. P., & Chiorino, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10333 · Cited by 31
Shriwash, N., Singh, P. K., Arora, S., Ali, S. M., Ali, S., & Dohare, R. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e01707 · Cited by 34
Lin, Y.-Y., Wang, C., Phan, N. N., Chiao, C.-C., Li, C.-Y., Sun, Z., Hung, J., Chen, Y., Yen, M., Weng, T., et al. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.46125 · Cited by 31
Sampson, N., Ruiz, C. F., Zenzmaier, C., Bubendorf, L., & Berger, P. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.040 · Cited by 31
Bender, R. J., & Gabhann, F. M. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0201-z · Cited by 32
Bai, Y., Qiao, L., Xie, N., Shi, Y., Liu, N., & Wang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184902 · Cited by 31
Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma
Yu, Y., Tsung, A., Liu, S., Nalesnick, M., Geller, D. A., Michalopoulos, G. K., & Luo, J. (2019) · Oncotarget · doi:10.18632/oncotarget.26918 · Cited by 31
Self-citationRusso, L. C., de Araujo, C. B., Iwai, L. K., Ferro, E. S., & Forti, F. L. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2016.06.028 · Cited by 30
Selenium‐binding protein 1 alters energy metabolism in prostate cancer cells
Elhodaky, M., Hong, L. K., Kadkol, S., & Diamond, A. M. (2020) · The Prostate · doi:10.1002/pros.24028 · Cited by 32
Zeng, W., Sun, H., Meng, F., Liu, Z., Xiong, J., Zhou, S., Fan, L., Hu, J., Hu, Z., & Liu, Z. (2015) · Europe PMC (PubMed Central) · Cited by 30
USP9X destabilizes pVHL and promotes cell proliferation
Zhang, C., Peng, Z., Zhu, M., Wang, P., Du, X., Li, X., Liu, Y., Jin, Y., McNutt, M. A., & Yin, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.11139 · Cited by 30
Rank discriminants for predicting phenotypes from RNA expression
Afsari, B., Braga-Neto, U. M., & Geman, D. (2014) · The Annals of Applied Statistics · doi:10.1214/14-aoas738 · Cited by 30
Predicting environmental chemical factors associated with disease-related gene expression data
Patel, C. J., & Butte, A. J. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-17 · Cited by 31
Principal Composite Kernel Feature Analysis: Data-Dependent Kernel Approach
Motai, Y., & Yoshida, H. (2012) · IEEE Transactions on Knowledge and Data Engineering · doi:10.1109/tkde.2012.110 · Cited by 29
Sha, K., Yeh, S., Chang, C., Nastiuk, K. L., & Krolewski, J. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4535 · Cited by 29
Giannareas, N., Zhang, Q., Yang, X., Na, R., Tian, Y., Yang, Y., Ruan, X., Huang, D., Yang, X., Wang, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34994-z · Cited by 30
Abildgaard, M. O., Borre, M., Mortensen, M. M., Ulhøi, B. P., Tørring, N., Wild, P. J., Kristensen, H., Mansilla, F., Ottosen, P. D., Dyrskjøt, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26097 · Cited by 29
Chen, J. L., Li, J., Stadler, W. M., & Lussier, Y. A. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000178 · Cited by 30
Molecular Cancer Phenotype in Normal Prostate Tissue
Schlomm, T., Hellwinkel, O., Buneß, A., Ruschhaupt, M., Lübke, A. M., Chun, F. K. ‐., Simon, R., Budäus, L., Erbersdobler, A., Graefen, M., et al. (2008) · European Urology · doi:10.1016/j.eururo.2008.04.105 · Cited by 29
Sørensen, K. D., Wild, P. J., Mortezavi, A., Adolf, K., Tørring, N., Heebøll, S., Ulhøi, B. P., Ottosen, P. D., Sulser, T., Hermanns, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2268 · Cited by 29
Rank discriminants for predicting phenotypes from RNA expressionPreprint
Afsari, B., Neto, U. B., & Geman, D. (2014) · Cited by 29
Cheng, L., Zhang, C., Tian, P. W., Tan, Q., Yu, W., Wang, Z., Zhang, Q., Zhang, Q., Zhong, M., Zhou, L., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01961-7 · Cited by 28
Liu, S., Wu, I., Yu, Y., Balamotis, M. A., Ren, B., Yehezkel, T. B., & Luo, J. (2021) · Communications Biology · doi:10.1038/s42003-021-02024-1 · Cited by 37
Self-citationTherapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer
Zoni, E., Astrologo, L., Ng, C. K. Y., Piscuoglio, S., Melsen, J. E., Grosjean, J., Klima, I., Chen, L., Snaar-Jagalska, E. B., Flanagan, K., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1220 · Cited by 28
RiGoR: reporting guidelines to address common sources of bias in risk model development
Kerr, K. F., Meisner, A., Thiessen‐Philbrook, H., Coca, S. G., & Parikh, C. R. (2015) · Biomarker Research · doi:10.1186/s40364-014-0027-7 · Cited by 31
Zhang, L., Zhang, X., Liu, C., Lǚ, K., Huang, Y., Wang, Y. D., Li, X., Zhang, L.-J., Liu, N., Jiang, H., et al. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5469 · Cited by 28
Upregulation of FAM84B during prostate cancer progression
Wong, N., Gu, Y. J., Kapoor, A., Lin, X., Ojo, D., Wei, F., Yan, J., Melo, J. D., Major, P. P., Wood, G. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15168 · Cited by 28
Genomics of prostate cancer: Is there anything to „translate”?
Kopper, L., & Tímár, J. (2005) · Pathology & Oncology Research · doi:10.1007/bf02893851 · Cited by 28
Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential
Miller, E. T., You, S., Cadaneanu, R. M., Kim, M., Yoon, J., Liu, S. T., Li, X., Kwan, L. C., Hodge, J. C., Quist, M. J., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06817-1 · Cited by 28
Cai, H., Zhang, B., Ahrenfeldt, J., Joseph, J. V., Riedel, M., Gao, Z., Thomsen, S. K., Christensen, D. S., Bak, R. O., Hager, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46370-0 · Cited by 29
CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer
Zambra, F. M. B., Biolchi, V., Brum, I. S., & Chies, J. A. B. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.04.031 · Cited by 30
Hsiao, J. J., Ng, B. H., Smits, M. M., Wang, J., Jasavala, R. J., Martinez, H. D., Lee, J., Alston, J. J., Misonou, H., Trimmer, J. S., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1201-5 · Cited by 27
Identifying differential correlation in gene/pathway combinations
Braun, R., Cope, L., & Parmigiani, G. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-488 · Cited by 27
Artificial Neural Network Analysis of DNA Microarray-based Prostate Cancer Recurrence
Peterson, L. E., Özen, M., Erdem, H., Amini, A. E., Gomez, L., Nelson, C. C., & Ittmann, M. (2005) · IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB) · doi:10.1109/cibcb.2005.1594929 · Cited by 27
Kuroyanagi, J., Shimada, Y., Zhang, B., Ariyoshi, M., Umemoto, N., Nishimura, Y., & Tanaka, T. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.07.033 · Cited by 30
Tang, Z., Dong, Q., Cui, Q., Papavassiliou, P., Wang, E.-D., & Wang, E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063676 · Cited by 30
Campa, V. M., Baltziskueta, E., Bengoa‐Vergniory, N., Gorroño‐Etxebarria, I., Wesołowski, R., Waxman, J., & Kypta, R. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2303 · Cited by 26
Park, A., Lee, J., Mun, S., Kim, D., Cha, B., Moon, K. T., Yoo, T., & Kang, H.-G. (2017) · Journal of Cancer · doi:10.7150/jca.19036 · Cited by 27
The STK38–XPO1 axis, a new actor in physiology and cancer
Martin, A. P. J., Aushev, V. N., Zalcman, G., & Camonis, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03690-w · Cited by 28
Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells
Kobayashi, T., Nakamura, E., Shimizu, Y., Terada, N., Maeno, A., Kobori, G., Kamba, T., Kamoto, T., Ogawa, O., & Inoue, T. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.06.146 · Cited by 30
MEIS1 functions as a potential AR negative regulator
Cui, L., Li, M., Feng, F., Yang, Y., Hang, X., Cui, J., & Gao, J. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.023 · Cited by 26
Metadata
- Authors
- Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., Michalopoulos, G., Becich, M., & Luo, J.-H.
- Affiliations
- University of Pittsburgh (US)
- From the Department of Pathology and Urology, University of Pittsburgh School of Medicine, and Biostatistics Center, University of Pittsburgh Cancer Institute and Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-15
- Volume
- 22
- Issue
- 14
- Pages
- 2790-2799
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2108426942
- Semantic Scholar
- 8be3bd0e253d2a736b72002f40143dec896e862a
- Cited by
- 758
- References
- 23
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 31 · 2023: 31 · 2022: 20 · 2021: 30 · 2020: 26 · 2019: 29 · 2018: 29 · 2017: 38 · 2016: 24 · 2015: 47 · 2014: 58 · 2013: 41 · 2012: 47
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (U01CA088110, 1U01 CA 88110-01, R01CA098249)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- prostate cancer, gene expression profiling, tumor aggressiveness, prostate carcinogenesis, gene expression patterns
- MeSH terms
- Adult, Cell Transformation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Invasiveness, Predictive Value of Tests, Prostate, Prostatic Neoplasms, Gene Expression, Disease Progression, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.